STAAR Surgical Company exhibits a markedly deteriorating profitability profile across all three core margins. While its current gross margin of 76.2% remains slightly above the ten‑year average of 74.5%, it has fallen for three consecutive years, signaling the first signs of cost or pricing pressure. The operating and net margins are far more concerning: operating margin is negative 19.2%, placing the company at the 0th percentile of its decade‑long range, and net margin sits at a deep -33.6%, also at the 0th percentile and well below breakeven. These trends reflect multi‑year structural erosion rather than short‑term cyclicality, as each metric has declined consistently over the past three years.

STAAR Surgical Company (STAA) exhibits a modest capital structure with a Debt-to-Equity ratio of 0.11x, essentially unchanged from its 10‑year average and positioned near the median (51st percentile). However, the Net Debt to EBITDA multiple has risen to 3.1x, well above its decade‑long average of 2.4x and sitting in the lower third of its historical distribution (30th percentile), indicating a tightening of cash‑flow coverage for debt obligations. While the overall leverage remains within generally acceptable limits for a low‑debt medical device firm, the combination of a deteriorating Debt-to-Equity trend and elevated Net Debt/EBITDA suggests that monitoring is warranted, especially if earnings volatility increases.

STAAR Surgical Company exhibits a deteriorating cash generation profile, with both operating cash flow (OCF) and free cash flow (FCF) turning negative in the most recent period. The OCF of -$49.96 million represents a 0th percentile placement within its ten‑year historical range, underscoring an acute short‑term cash burn that is atypical for a company with historically stable cash conversion. Compounding this weakness, free cash flow declined by $32.38 million year‑over‑year, indicating that capital expenditures and other outflows are now exceeding the cash generated from core operations. On the liquidity front, the firm maintains relatively high absolute levels of short‑term assets, as reflected in a current ratio of 4.55x and a quick ratio of 3.74x, both well above conventional safety thresholds (typically >1.5x). However, these ratios have been on a three‑year downward trajectory, with the current ratio falling by 0.69 points YoY and the quick ratio dropping by 0.88 points YoY, signaling a gradual erosion of the cushion that protects against cash shortages. The cash ratio remains stable at 2.24x, offering some reassurance that cash on hand can cover immediate liabilities.

STAAR Surgical Company’s earnings quality raises concerns, as operating cash flow (OCF) covers only 43% of net income, far below the 80% threshold that signals robust cash backing. The low OCF/NI ratio suggests a sizable portion of reported profit is driven by non‑cash items or aggressive accounting, which could impair the company’s ability to fund operations and growth without external financing. Additionally, stock‑based compensation (SBC) now consumes 12.8% of revenue—well above the historical average of 7.3% and exceeding the 10% comfort level—indicating a growing dilutionary expense that erodes profitability.